Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Theracos
Approximately 130 investigative sites globally are planned to participate in this study.
An estimated 1650 subjects with inadequately controlled T2DM and an elevated risk of cardiovascular adverse events will be randomized to bexagliflozin tablets, 20 mg, or placebo in a ratio of 2:1 in addition to the background anti-diabetic medications.
The study is an event-driven trial. The treatment period will end when the last randomized subject has completed at least 52 weeks of treatment and a total of at least 134 subjects have experienced a cardiac event.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with a diagnosis of T2DM
Subjects who have had a stable treatment regimen for T2DM for the past 3 months
Subjects who present with at least one of the following 3 histories:
Group 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently smoking, reduced kidney function, or cholesterol problems
You may not be if
Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young
History of genitourinary tract infections
Evidence of abnormal liver function
History of MI, stroke or hospitalization for heart failure in the past 3 months
Prior kidney transplant or evidence of kidney problems